1. Basic introduction: Shandong Siwei Group is a high-tech production base with Shandong Siwei Pharmaceutical Co., Ltd. and Shandong Yatai Pharmaceutical Co., Ltd. as the group; Shandong Siwei Pharmaceutical Marketing Company, Shandong Siwei Pharmaceutical Hong Kong Co., Ltd., Taiwan Province Yu Xiang Industrial Co., Ltd., Japanese Hexing Products Co., Ltd. and Moscow Lijinji Global Enterprise Co., Ltd. are the marketing carriers of the group; Beijing 1+X Institute of Medicine and Taian Yu Xiang Institute of Traditional Chinese Medicine are the research centers of the Group. Shandong Siwei Pharmaceutical Hong Kong Co., Ltd. is the capital operation center; Yu Xiang Internet Commerce Co., Ltd. is a comprehensive group enterprise integrating scientific research, production, economy and trade, information and capital operation, covering 13 countries and regions.
2. Negative social impact: The company was exposed in CCTV before, which caused great negative impact. But the company also clarified that the final outcome was gone.
3. Good reputation: In 2007, the credit rating of this enterprise was "excellent".
4. Listing plan: As early as around 2005, we have been cooperating with Minsheng Securities, hoping to gain a place in the capital market. Three years is still fruitless, and it seems that the road is difficult.
Comprehensive analysis: shareholders are scattered, marketing companies should not be directly commanded by the headquarters, and go their separate ways, and drug popularization is still lacking. CCTV reports have had a negative impact. Personal performance is not clear. Comprehensive analysis, listing is still difficult.